Corbus Pharmaceuticals Bolsa (NASDAQ: CRBP)

Últimas noticias sobre Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

News

Trading Ideas

CHTR

Berkshire Hathaway 13F Shows Reduced Stake In Bank Of America By 23% To 797.7M Shares, Worth $31.7B; Reduced Stake In Charter Communications By 26% To 2.82M Shares, Worth $914.5M; Reduced Stake In Nu Holdings By 19% To 86.4M Shares, Worth $1.18B; Reduced Stake In Occidental Petroleum By 18%, Now Valued At $13.16B

Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.25 by 24 percent. The company reported quarterly sales of $33.391 million which beat the analyst consensus estimate of $31.750 million by 5.17 percent. This is a 33.02 percent decrease over sales of $49.854 million the same period last year.

Earnings

Earnings Beats

CWCO

Consolidated Water Co Q3 2024 GAAP EPS $0.31 Beats $0.25 Estimate, Sales $33.391M Beat $31.750M Estimate

NMHI

Nature's Miracle Holding Q3 EPS $(0.09), Sales $3.05M Up From $2.69M YoY

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) with a Buy and maintains $9 price target.

Price Target

Analyst Ratings

KAPA

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

<a href="https://truthsocial.com/@realDonaldTrump/113483513301208163" title="https://truthsocial.com/@realDonaldTrump/113483513301208163">https://truthsocial.com/@realDonaldTrump/113483513301208163</a>

Macro Notification

Politics

General

CORRECTION: Trump Picks Jay Clayton For U.S. Attorney For The Southern District Of New York

Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares are up 23.4% to $89.54 in November following the company's <a href="https://www.benzinga.com/news/earnings/24/11/41754359/astera-labs-stock-is-ripping-higher-today-whats-going-on">impressive third-quarter earnings</a> beat Wall Street expectations, reinforcing its role as a critical player in AI infrastructure. 
What To Know: Astera reported earnings of 23 cents per share, exceeding the estimated 17 cents, alongside revenue of $113.1 million, up 206% year-over-year and well above analyst forecasts of $97.4 million. 
CEO Jitendra Mohan highlighted that the company achieved its fifth consecutive quarter of record-breaking revenue, with sales rising 47% from the previous quarter, driven by new growth in AI connectivity solutions.
Astera's latest product, the Scorpio Smart Fabric Switch, is central to its strategy. These switches are designed to enhance data transfer speeds between GPUs, CPUs and storage devices, addressing critical needs in AI data centers where performance demands are skyrocketing.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What Else: The company's strong performance and promising product pipeline prompted multiple analysts to raise their price targets.
JPMorgan increased its target to $110 per share, while Deutsche Bank, Barclays and others <a href="https://www.benzinga.com/quote/ALAB/analyst-ratings">made upward revisions</a>. 
Astera's revenue forecast for the fourth quarter of $126–$130 million, alongside expected earnings of 25 cents to 26 cents per share, has added momentum to investor enthusiasm.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
<h2 class="wp-block-heading">How To Buy ALAB Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Astera Labs&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ALAB has a 52-week high of $100.09 and a 52-week low of $36.22.

ALAB

Astera Labs (ALAB) Stock Is Up 23% This Month: What's Going On?

CV Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB">CVSI</a>), a <a href="http://benzinga.com/topic/hemp">hemp</a>-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.
<h4 class="wp-block-heading">Q3 2024 Financial Highlights</h4>
<ul>
<li>Revenue: $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">$4 million in Q2 2024</a>.</li>
<li>Net loss: $456,000, slightly higher than the $447,000 loss in Q3 2023.</li>
<li>Adjusted EBITDA: Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.</li>
<li>Gross profit: $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last year.</li>
</ul>
<h3 class="wp-block-heading">New Product Lines Boost Growth</h3>
Operating with a cash balance of $1 million, CV Sciences recorded an adjusted EBITDA loss of $75,000, <a href="https://www.benzinga.com/markets/cannabis/24/03/37988133/hemp-focused-wellness-co-moves-closer-to-profitability-reports-flat-2023-revenue-increase-in-gro">inching closer</a> to cash flow break-even.
Furthermore, the company's recent launches, including the cannabinoid-free +PlusHLTH supplement line, target cognitive health, stress relief and metabolism support. Additionally, CV Sciences expanded its pet health segment with hip, joint and calming chews, aiming to capture a broader consumer base.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Management Commentary</h3>
CEO Joseph Dowling highlighted the <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">steady core revenue</a> in a challenging environment, noting new products and acquisitions as positioning factors for growth in 2025. &#8220;Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow,&#8221; Dowling <a href="https://www.prnewswire.com/news-releases/cv-sciences-inc-reports-third-quarter-2024-financial-results-302305079.html">said</a> in a press release.
Read Also: <a href="https://www.benzinga.com/24/11/41971875/cbd-pioneer-charlottes-web-narrows-loss-in-q3-focuses-on-long-term-growth-amid-challenging-cannabis-industry-environment">CBD Pioneer Charlotte&#8217;s Web Narrows Loss In Q3, Focuses On Long-Term Growth</a>
"We look forward to organically grow our business and pursue additional M&amp;A opportunities in the near future to improve our top-line revenue, profitability and shareholder value," he added.
<h3 class="wp-block-heading">CV Sciences Holds Top Market Spot</h3>
In Q3, CV Sciences further solidified its market position, maintaining top-seller status in the natural products retail channel, according to SPINS data. The company also secured $0.9 million in financing from Streeterville, aimed at fueling operational and product expansion.
CVSI Price Action CVSI's shares were trading 7.73% lower at $0.04235 per share at the time of this writing around 12:35 PM ET Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth">CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</a></li>
</ul>

Cannabis

CVSI

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

RIVN

iShares Trust Barclays 20+ Year Treasury Bond Fund

Soros Fund Management 13F Shows Exited Position In SPDR S&P 500 ETF, Previously Holding 450,000 Shares; Exited Stake In Rivian Automotive Call Options, Previously Holding 5,450,000 Shares; Exited Put Position In Ishares 20+ Year Treasury Bond ETF, Previously Holding 360,000 Shares; Exited Stake In Westrock Co, Previously Holding 3,342,953 Shares;  Exited Stake In Livongo Health Convertible Notes, Previously Holding $45M In Principal

PMNT

Perfect Moment Q2 EPS $(0.17) Up From $(0.29) YoY; Revenue $3.833M Down From $5.888M YoY

Canaccord Genuity analyst Joseph Vafi maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $22 to $32.

Canaccord Genuity Maintains Buy on Hut 8, Raises Price Target to $32

PXLW

Pixelworks Enters $10M "At-The-Market" Equity Offering Agreement With Roth Capital, Allowing Periodic Common Stock Sales With 2.5% Commission; Roth To Act As Sales Agent

GOOGL

LBRDA

Soros Fund Management 13F Shows Decreased Stake In Rivian Automotive Convertible Notes By 21% To $155.9M In Principal; Decreased Stake In Wayfair Convertible Notes By 11% To $119.5M In Principal; Decreased Stake In Liberty Broadband Corp By 19% To 1,119,893 Shares; Decreased Stake In Alphabet Class A By 43% To 517,890 Shares; Decreased Put Position In Ishares IBoxx High Yield Corporate Bond ETF By 40% To 1,500,000 Shares

Discover Financial Reports $100.7B In Credit Card Loans As Of October 2024, Up From $98.7B YoY; Average Balances Remain Stable At $100.2B; Net Principal Charge-Off Rate Drops To 4.31% With Disaster Relief Impact, Though Up From 4.42% YoY; Delinquency Rate Rises Slightly To 3.87%

Management

Zillow Group Appoints Jun Choo As COO

Offerings

GYRE

Gyre Therapeutics Files For Up To $150M Mixed Shelf

WIIM

IZEA

IZEA Worldwide shares are trading lower after the company reported worse-than-expected Q3 financial results.

BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.58) by 32.76 percent.

BKYI

BIO-key Intl Q3 2024 Adj EPS $(0.39) Beats $(0.58) Estimate

TFFP

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.52) by 53.85 percent.

ENVB

Enveric Biosciences Q3 2024 GAAP EPS $(0.24) Beats $(0.52) Estimate

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricte...

Corbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity Week

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Corbus Pharmaceuticals (CRBP – Research Report). The associated ...

Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment with a Buy Rating

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Buy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward Scenario

As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations th...

Corbus Pharmaceuticals expects cash to fund operations through 3Q27

"We continue to make steady and significant progress across our pipeline," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We expect t...

Corbus Pharmaceuticals reports Q3 EPS ($1.15), consensus (95c)

An update from Corbus Pharmaceuticals ( ($CRBP) ) is now available. Corbus Pharmaceuticals, an oncology and obesity-focused company, reported a net...

Corbus Pharmaceuticals Reports Q3 2024 Financial Results

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Corbus Pharmaceuticals (CRBP) to $75 from $80 and keeps a Buy rating on...

Corbus Pharmaceuticals price target lowered to $75 from $80 at H.C. Wainwright

In a report released on November 7, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), wit...

Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

ALKS

APLS

CRBP

DERM

ELAB

NKTR

NONOF

RPRX

SNYNF

TKPHF

VKTX

VRCA

VRNA

The Future of Medicine: Key Biotech Stocks to Watch

Press Releases

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

Transforming Oncology: Stocks to Watch in the Oncology Sector

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Health Care

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

ACON

ATNM

OSTX

PBYI

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Corbus Pharmaceuticals

Noticias

Últimas noticias sobre Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL